Aytu BioScience, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2015, compared with fiscal 2014. Although the request metadata says “2014 Q4,” this is an annual filing and does not provide a standalone fourth-quarter results summary. The filing identifies the registrant as Aytu BioScience, Inc.
Business context and significant changes
Aytu is a specialty healthcare company focused on urology. Its principal assets are Zertane, a premature-ejaculation drug candidate; FDA-approved ProstaScint, a prostate-cancer imaging product; and RedoxSYS, a research-use diagnostic system, with MiOXSYS under development for male infertility.
- In April 2015, the company completed a reverse-merger transaction with Vyrix and Luoxis, shifting from Rosewind’s former business to healthcare. It reincorporated in Delaware and completed a 1-for-12.174 reverse stock split in June.
- In May 2015, it acquired ProstaScint from Jazz Pharmaceuticals. The company reported limited ProstaScint and RedoxSYS product revenue after the acquisition.
- Historical results largely reflect Vyrix and Luoxis carve-out financials before the merger, including allocated costs and no carve-out of cash. Management cautions these results may not represent future standalone performance.
Financial results and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Total revenue | $261,782 | $58,929 |
| Operating loss | $7,632,320 | $6,346,834 |
| Net loss | $7,723,404 | $5,578,690 |
| Net loss per share | $0.84 | $0.80 |
| Cash used in operating activities | $6,634,214 | $5,501,962 |
| Cash and cash equivalents at year-end | $7,353,061 | $2,639,650 |
- FY2015 revenue included $176,068 of product and service sales and $85,714 of license revenue. FY2014 revenue was license revenue. FY2015 cost of sales was $88,109; the resulting $173,673 difference from total revenue is not a like-for-like product gross margin because revenue includes license amortization.
- Research and development expense, including related-party research, was approximately $3.423 million, down from $4.059 million. General and administrative expense rose to $4.383 million from $2.347 million, chiefly reflecting merger-related, professional, staffing and commercialization costs.
- At June 30, 2015, current assets were $8.084 million and current liabilities were $1.479 million; total liabilities were $2.610 million. The balance sheet showed no Ampio notes payable at year-end; prior Ampio debt was converted or otherwise settled through the merger arrangements. Accumulated deficit was $18.381 million.
- FY2015 investing cash outflow was $1.005 million, mainly the $1.0 million ProstaScint upfront payment. Financing provided $12.353 million, largely from Ampio funding and stock-related transactions.
- After year-end, Aytu raised $5.2 million through unsecured convertible notes. The notes carry 8% interest for six months and 12% thereafter, subject to a possible 14% rate if a registration statement is not filed within the specified period; conversion terms can result in dilution.
Outlook, commentary and key risks
- Management expected research and development expense to rise in FY2016 as Zertane trials ramped up, and general and administrative expense to increase with company growth. It planned to submit a Zertane IND in the second half of 2015 and pursue two U.S. Phase 3 trials, each expected to enroll approximately 350–400 participants.
- Management projected that cash, Ampio’s stated $5.0 million funding commitment and the post-year-end note financing could support operations through calendar 2016 and into 2017, but said the estimate depended on assumptions and that additional capital would be needed. The company cited an expected cash burn of about $400,000–$500,000 per month and warned that financing might not be available on acceptable terms.
- The filing describes substantial execution and regulatory uncertainty: Zertane still required U.S. trials and FDA approval, and contains tramadol, a Schedule IV controlled substance with potential safety, abuse-monitoring and distribution constraints. MiOXSYS required FDA clearance for U.S. clinical marketing; RedoxSYS research-market commercialization and ProstaScint sales growth were not assured.
- Other material risks include limited operating history and recurring losses; dependence on outside financing, collaborators and contract manufacturers; ProstaScint reimbursement and manufacturing-transfer risks; competition; and intellectual-property uncertainty. Ampio owned 81.5% of Aytu at June 30, 2015, creating control and related-party risks.
- Management did not assess disclosure controls or internal control over financial reporting as of year-end, citing the recent merger and limited time to implement controls. The filing says the first internal-control assessment was expected for FY2016. The auditor issued an unqualified opinion on the financial statements, not an opinion on internal-control effectiveness.
Important facts for investors to verify
- Whether the $5.0 million Ampio funding commitment was funded, and how the $5.2 million convertible notes’ interest, conversion, registration and dilution terms developed.
- Actual cash burn, financing needs and runway compared with management’s projection through 2016 and into 2017.
- Progress and outcomes of Zertane’s IND and U.S. Phase 3 program, including FDA requirements, trial costs and tramadol-related controls.
- ProstaScint sales, reimbursement coverage, inventory transfer, manufacturing continuity and any contingent payments tied to future sales.
- MiOXSYS clinical validation and FDA pathway, and the revenue and adoption achieved by RedoxSYS in the research market.
- Whether post-merger controls were implemented and assessed, and how Ampio’s control and related-party arrangements changed.